Breast Cancer Research and Treatment

, Volume 90, Issue 3, pp 215–221

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer

Authors

  • Sun Young Rha
    • Cancer Metastasis Research CenterYonsei University College of Medicine
    • Brain Korea 21 Project for Medical SciencesYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Yong Hwa Moon
    • Brain Korea 21 Project for Medical SciencesYonsei University College of Medicine
    • Department of Internal MedicineYonsei University College of Medicine
  • Hei Chul Jeung
    • Cancer Metastasis Research CenterYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Yong Tae Kim
    • Department of Internal MedicineYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Joo Hyuk Sohn
    • Department of Internal MedicineYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Woo Ick Yang
    • PathologyYonsei University College of Medicine
  • Chang Ok Suh
    • Radiation OncologyYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Gwi Eon Kim
    • Radiation OncologyYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
  • Jae Kyung Roh
    • Cancer Metastasis Research CenterYonsei University College of Medicine
    • Brain Korea 21 Project for Medical SciencesYonsei University College of Medicine
    • Department of Internal MedicineYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
    • Cancer Metastasis Research CenterYonsei University College of Medicine
    • Brain Korea 21 Project for Medical SciencesYonsei University College of Medicine
    • Department of Internal MedicineYonsei University College of Medicine
    • Yonsei Cancer CenterYonsei University College of Medicine
Article

DOI: 10.1007/s10549-004-2468-4

Cite this article as:
Rha, S.Y., Moon, Y.H., Jeung, H.C. et al. Breast Cancer Res Treat (2005) 90: 215. doi:10.1007/s10549-004-2468-4

Summary

Purposes

We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy.

Methods

A weekly infusion of gemcitabine at 850 mg/m2for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles.

Results

Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2–25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group.

Conclusion

Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.

Keywords

breast cancergemcitabineheavily pretreatedmonotherapysalvage

Copyright information

© Springer 2005